Try a new search

Format these results:

Searched for:

person:mcneem03

in-biosketch:true

Total Results:

2


Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis

Kim, Youn H; Prince, H Miles; Whittaker, Sean; Horwitz, Steven M; Duvic, Madeleine; Bechter, Oliver; Sanches, Jose A; Stadler, Rudolf; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Eradat, Herbert; Pinter-Brown, Lauren C; Ortiz-Romero, Pablo L; Akilov, Oleg E; Trotman, Judith; Taylor, Kerry; Weichenthal, Michael; Walewski, Jan; Fisher, David; McNeeley, Marise; Gru, Alejandro A; Brown, Lisa; Palanca-Wessels, M Corinna; Lisano, Julie; Onsum, Matthew; Bunn, Veronica; Little, Meredith; Trepicchio, William L; Dummer, Reinhard
INTRODUCTION/BACKGROUND:Mycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, can lead to disfiguring lesions, debilitating pruritus and frequent skin infections. This study assessed response to brentuximab vedotin in patients with MF in the phase III ALCANZA study. METHODS: ≥ 10% (all biopsies with ≥10% CD30 expression) and baseline LCT present or absent. Efficacy analyses were the proportion of patients with objective response lasting ≥4 months (ORR4) and progression-free survival (PFS). RESULTS: ≥ 10% (15.5 versus 3.9 months), with LCT (15.5 versus 2.8 months) and without LCT (16.1 versus 3.5 months). Safety profiles were generally comparable across subgroups. CONCLUSION/CONCLUSIONS:These exploratory analyses demonstrated that brentuximab vedotin improved rates of ORR4 and PFS versus physician's choice in patients with CD30-positive MF and ≥1 biopsy showing ≥10% CD30 expression, regardless of LCT status. CLINICAL TRIAL REGISTRATION/BACKGROUND:Clinicaltrials.gov, NCT01578499.
PMID: 33794441
ISSN: 1879-0852
CID: 4952202

Penetrating ulcer of ascending thoracic aorta in syphilis [Case Report]

Saleem, Mohammad A; McNeeley, Marise; Zias, Elias; Pucillo, Anthony; Ro, Jae H; Weiss, Melvin B
Penetrating aortic ulcers (PAUs) are rare exotic pathological entities, classically located in the descending thoracic aorta. Their association with syphilis has never been reported. We describe a first case of a patient with cardiovascular syphilis presenting as PAU in the ascending aorta
PMID: 14696153
ISSN: 1522-1946
CID: 102172